Hims & Hers Health, Inc.
Panjang
Telah dikemas kini

HIMS - June 24 Qullamaggie Breakout and Episodic Pivot

345
I believe the inclusion of the compounded GLP-1 drug as part of their product offerings will driving strong sales and membership numbers in the next few months.

1) Their compounded GLP-1 is significantly cheaper
2) Their platform makes it easier and more accessible to purchase
3) It is lifestyle related so monthly recurring purchases is encouraged
4) HIMS is essentially a DTC business where capturing market share is crucial at this stage. In 2021 it was reported that they spend 48% of their revenue on marketing.

As long as they can secure recurring purchases with a solid Average Order Value (AOV), they can gradually reduce and optimise expenses for new acquisitions once they have captured a significant market share. Not to mention the cross sell potential and the lower advertising costs for existing customers

This is part of a Qullamaggie Breakout and Episodic Pivot study I am currently conducting

Source
Nota
Initially, I focused on the tightening candles. However, the price momentum, reflected in the gap up, combined with my conviction based on the fundamental reasons for the stock's rise. Consequently, I entered the trade with confidence. If the price pulls back due to broad market movements, I'll be ready to re-enter another probe bet once momentum returns.
Dagangan ditutup secara manual
I closed this trade at breakeven because the price didn't follow the expected trend and started to consolidate. I will re-enter when the momentum aligns with my hypothesis and conviction.

Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.